TP53 and myelodysplastic syndrome: Although the mechanism and specificity of APR-246 for p53MUT tumor cells has been questioned, the FDA granted breakthrough therapy designation for APR-246 in combination with azacitidine for the treatment of patients with myelodysplastic syndromes (MDS) with a susceptible TP53 mutation based on a promising early phase II study (NCT03588078)[71].